Servier strengthens its R&D pipeline with Symphogen acquisition6 Apr 2020
Symphogen becomes the antibody center of excellence within Servier.
Servier, an independent international pharmaceutical company, is to acquire Symphogen A/S, a leader in therapeutic antibody discovery.
According to Servier, the move will strengthen its antibody capabilities, as it is set to gain full ownership of Symphogen’s proprietary pipeline of oncology and immuno-oncology programs and the company's antibody discovery and development platform. The acquisition will also ensure that Symphogen’s antibody discovery and early-development platform is fully utilized.
Once the acquisition is complete, Symphogen will become Servier’s antibody center of excellence for its therapeutic areas; it will also operate as a standalone organization within the Servier Group, maintain its headquarters in Ballerup, Denmark, and continue to rely on its current and experienced employees.
“The acquisition of Symphogen is an important step for Servier to meet its strategic ambitions to become a recognized player in oncology. Antibody-based therapies remain a key therapeutic modality within oncology and immuno-oncology, and with Symphogen’s strong antibody capabilities, this acquisition will boost significantly our R&D in oncology and in our other therapeutic areas," said Olivier Laureau, President of Servier.
Servier and Symphogen have been engaged in a strategic immuno-oncology collaboration for more than 2 years.
HKBU scientists develop technique to eliminate drug side effects
19 May 2020
The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.Read more
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit
18 May 2020
CDMO is contracted to produce multiple clinical batches from German facilityRead more
Characterizing virus and virus-like particles
12 May 2020
New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.Read more
AI technology company launches with Novartis and Sarepta deals
11 May 2020
Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.Read more
Bio-Rad launches anti-certolizumab pegol antibodies
5 May 2020
Using this critical antibody reagent at the preclinical stage of development will minimize the need to revalidate assays with different reagents at the clinical development stage.Read more
BERG named visionary in first-ever Frost Radar AI in Drug Discovery report
13 Apr 2020
The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.Read more
AstraZeneca "incredibly excited" by lung cancer treatment trial
13 Apr 2020
Independent Data Monitoring Committee (IDMC) recommends unblind Phase III trial of Tagrisso 2 years ahead of schedule.Read more
German pharma companies are meeting the corona "stress test"
7 Apr 2020
The head of the leading German pharmaceutical industry organization says German firms are working top-speed to find coronavirus medications.Read more
World’s leading biobanks join a global network to advance personalized healthcare research
6 Apr 2020
The platform enables collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.Read more
Evotec expands into gene therapy with new Austrian unit
6 Apr 2020
Evotec has established a dedicated gene therapy-based R&D site in Orth an der Donau, Austria with the immediate focus of spearheading a partnership with Japan’s Takeda to support its research projects, the German drug discovery firm said Monday.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation